Bioam Gestion

Bioam Gestion

Bioam Gestion was established in 1998 by Olivier de Fougeroux, a former financial executive who positioned the firm at the intersection of French institutional capital and early-stage European life sciences innovation. Unlike generalist venture platforms, Bioam was purpose-built for a single sector, launching its first dedicated fund in 1999 to target therapeutics, medical devices, and enabling technologies. The firm operates from Paris and has historically drawn limited partners from European institutional investors, family offices, and development banks seeking exposure to deeptech healthcare. Strategy centers on venture and growth-stage investments in unlisted European companies across three sub-verticals: biotechnology, medical technology and digital health. Bioam manages a series of thematic funds, including vehicles focused on rare diseases and agritech-adjacent biology. Confirmed portfolio positions, per the firm's official communications and public record, include Sensorion, a gene-therapy company targeting hearing loss; Theraclion, a developer of echotherapy devices; and Erytech Pharma, a Lyon-based clinical-stage biopharma. Geographic coverage extends from France into Switzerland, Germany, and the Nordic region, reflecting a pan-European investment mandate that looks for deep-tech assets anchored to academic research hubs. Team scale and current deployment figures are not publicly disclosed, and Bioam maintains a low-profile operational footprint typical of a specialized asset manager operating below the radar of large aggregators. The firm has not announced new fund closes or leadership transitions in the 2023–2025 window, and observable personnel data remains thin. Its regulatory filings and limited press coverage depict a stable structure — a lean team executing follow-on rounds for existing portfolio companies rather than raising successive flagship vehicles at large scale. What structurally differentiates Bioam Gestion is its single-sector endurance. Most European life-science venture firms that launched in the late 1990s either broadened into generalist tech or were absorbed by larger platforms. Bioam continues to operate as a standalone, sector-concentrated manager 25 years after founding, holding a portfolio that spans the attrition cycles of biotech fundraising. This longevity provides a database of clinical-trial outcomes and regulatory relationships that a younger entrant cannot replicate, even if total assets under management remain undisclosed.